Kane Investment Management’s Thermo Fisher Scientific TMO Stock Holding History

Kane Investment Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,531	Closed	-$762K	–	102
2025 Q1	$762K	Buy	1,531 +95	+7%	+$51.5K	0.37%	60
2024 Q4	$747K	Buy	+1,436	New	+$790K	0.42%	58

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kane Investment Management's TMO Position: Q2 2025 in Review

Kane Investment Management sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 1,531 shares — an estimated $762K sold.

Kane Investment Management first reported a position in TMO in Q4 2024 and held it in 2 quarters. The position peaked at $762K in Q1 2025. 2,454 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

Kane Investment Management reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
Kane Investment Management sold 1,531 Thermo Fisher Scientific shares in Q2 2025, an estimated $762K.
Kane Investment Management first reported a position in Thermo Fisher Scientific in Q4 2024 and held it in 2 quarters.
Kane Investment Management's Thermo Fisher Scientific position peaked at $762K in Q1 2025.
2,454 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on Kane Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.